Impact of SARS-CoV-2 infection on patients with hematological malignancies: a retrospective study

References

• Coronavirus disease (COVID-19) pandemic. 2023. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Hu Y, Wang L, Cui Q, et al. COVID-19 in hematologic malignancies: big challenges. Clin Hematol Int. 2020;2(4):173–175. doi:10.2991/chi.k.200919.001
   PubMedGoogle Scholar
• Hus I, Salomon-Perzyński A, Tomasiewicz K, et al. The management of hematologic malignancies during the COVID-19 pandemic. Expert Opin Pharmacother. 2021;22(5):565–582. doi:10.1080/14656566.2020.1849143
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892. doi:10.1182/blood.2020008824
   PubMed Web of Science ®Google Scholar
• Azhdari Tehrani H, Ramezaninejad S, Mardani M, et al. Hematologic malignancies and COVID-19 infection: a monocenter retrospective study. Health Sci Rep. 2022;5(3):e638. doi:10.1002/hsr2.638
   PubMedGoogle Scholar
• Papakonstantinou E, Dragoumani K, Efthimiadou A, et al. Haematological malignancies implications during the times of the COVID-19 pandemic. Oncol Lett. 2021;22(6):856. doi:10.3892/ol.2021.13117
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. Jama. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. Jama. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• García-Suárez J, de la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133. doi:10.1186/s13045-020-00970-7
   PubMed Web of Science ®Google Scholar
• Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi:10.1016/S0140-6736(20)31173-9
   PubMed Web of Science ®Google Scholar
• He, Y, Zhang F, Liu Y, et al. Clinical characteristics of mild patients with breakthrough infection of omicron variant in China after relaxing the dynamic zero COVID-19 policy. Vaccines. 2023;11(5):968. doi:10.3390/vaccines11050968
   Web of Science ®Google Scholar
• COVID-19 clinical and surveillance data — December 9, 2022 to January 30, 2023, China. 2023.
   Google Scholar
• SARS-CoV-2 infection diagnosis and treatment protocol (trial version 10). 2023. Available from: https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm
   Google Scholar
• Acar IH, Guner SI, Ak MA, et al. Impact of COVID-19 on outcomes of patients with hematologic malignancies: a multicenter, retrospective study. Mediterr J Hematol Infect Dis. 2022;14(1):e2022074. doi:10.4084/MJHID.2022.074
   PubMedGoogle Scholar
• Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi:10.1186/s13045-021-01177-0
   PubMed Web of Science ®Google Scholar
• Jain A, Nayak L, Kulkarni UP, et al. Outcomes of patients with hematologic malignancies and COVID-19 from the hematologic cancer registry of India. Blood Cancer J. 2022;12(1):2. doi:10.1038/s41408-021-00599-w
   PubMed Web of Science ®Google Scholar
• Piñana JL, Martino R, García-García I, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21. doi:10.1186/s40164-020-00177-z
   PubMed Web of Science ®Google Scholar
• Westblade LF, Brar G, Pinheiro LC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38(5):661–671.e2. doi:10.1016/j.ccell.2020.09.007
   PubMed Web of Science ®Google Scholar
• Wang XA, Binder AF, Gergis U, et al. COVID-19 in patients with hematologic malignancies: a single center retrospective study. Front Oncol. 2021;11:740320. doi:10.3389/fonc.2021.740320
   PubMed Web of Science ®Google Scholar
• Naimi A, Yashmi I, Jebeleh R, et al. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis. J Clin Lab Anal. 2022;36(5):e24387. doi:10.1002/jcla.24387
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 omicron variant. Nature. 2022;603(7902):700–705. doi:10.1038/s41586-022-04462-1
   PubMed Web of Science ®Google Scholar
• Borno HT, Kim MO, Hong JC, et al. COVID-19 outcomes among patients with cancer: observations from the University of California Cancer Consortium COVID-19 project outcomes registry. Oncologist. 2022;27(5):398–406. doi:10.1093/oncolo/oyac038
   PubMed Web of Science ®Google Scholar
• Yeoh CB, Lee KJ, Rieth EF, et al. COVID-19 in the cancer patient. Anesth Analg. 2020;131(1):16–23. doi:10.1213/ANE.0000000000004884
   PubMed Web of Science ®Google Scholar
• Isidori A, de Leval L, Gergis U, et al. Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned. Front Oncol. 2020;10:1439. doi:10.3389/fonc.2020.01439
   PubMed Web of Science ®Google Scholar
• Booth S, Curley HM, Varnai C, et al. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br J Haematol. 2022;196(4):892–901. doi:10.1111/bjh.17937
   PubMed Web of Science ®Google Scholar
• Harris CE, Vijenthira A, Ong SY, et al. COVID-19 and other viral infections in patients with hematologic malignancies. Am Soc Clin Oncol Educ Book. 2023;43:e390778. doi:10.1200/EDBK_390778
   PubMedGoogle Scholar
• Expert opinions for specific hematologic malignancies. 2023. Available from: https://ehaweb.org/covid-19/covid-19-recommendations/recommendations-for-specific-hematologic-malignancies/
   Google Scholar
• Salmanton-García J, Marchesi F, Gomes da Silva M, et al. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. E Clinic Med. 2023;58:101939. doi:10.1016/j.eclinm.2023.101939
   Google Scholar
• Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8(9):e70. doi:10.1016/S2213-2600(20)30354-4
   PubMed Web of Science ®Google Scholar
• El Zein S, Chehab O, Kanj A, et al. SARS-CoV-2 infection: initial viral load (iVL) predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients corresponds with slowing of the pandemic. PLoS One. 2021;16(9):e0255981. doi:10.1371/journal.pone.0255981
   PubMed Web of Science ®Google Scholar
• Bhargava A. Dynamic aspects of ORF1ab and N RNA cycle threshold values among COVID-19 patients in China. Infect Genet Evol. 2021;87:104657. doi:10.1016/j.meegid.2020.104657
   PubMed Web of Science ®Google Scholar
• Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270–2279. doi:10.1093/eurheartj/ehaa1103
   PubMed Web of Science ®Google Scholar